Log In
BCIQ
Print this Print this
 

TAR-1

  Manage Alerts
Collapse Summary General Information
Company Tel Aviv University
DescriptionSingle-chain antibody fragment against a mutant form of p53
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/02/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today